2 Drug Stocks To Buy Now

Bret Jensen submits: Company Overview : Amgen Inc., (AMGN) a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation.

By John Mylant: Amgen (AMGN) has grown tremendously over the last six weeks. It looks like a solid investment as we explore how smart they have been at making money by looking at some key ratios. But climbing close to its 52 week high brings out a little caution in us. Therefore we will give you some advice on protecting your stocks if you are interested in investing in AMGN by using options.

John Mylant submits: Amgen Inc. (AMGN), a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada.

ByShankar N: Overview Amgen, Inc. (AMGN) incorporated in 1980 is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Headquartered in Thousand Oaks California, the biotech major employs approximately 18,000 worldwide.

Paul Price submits:Amgen Inc. (AMGN - $56.90) is the world’s largest independent biotechnology medicines company. They discover, develop, manufacture and market medicines for serious illnesses. Their focus is on human therapeutics and AMGN concentrates on medicines based on advances in cellular and molecular biology. 2009 R&D investment was about $2.9 billion or 20% of total sales.

By Stone Fox Capital:When Amgen (AMGN) reported earnings a few weeks back, the company reported a very surprising stat to most investors. It has spent billions on a stock buyback at shockingly lower stock prices.

By Bret Jensen:The market opened down on Friday, despite a decent jobs report that contained upward revisions to the two previous jobs reports. It is on days like these that I take out my shopping list and pick up shares on the cheap. One stock on my radar these days due to its low valuations and rapidly growing earnings is Timken (TKR).

Jim Van Meerten submits: One of the most consistently rising stocks on the NASDAQ 100 list according to Barchart is Amgen (AMGN) with 15 advances in the last 20 sessions. The company has well established brand drugs like Aranesp, Epogen and Embrel and looks to bring new drugs into the pipeline. My only concern is what health care reform may mean to the whole pharma industry. The momentum recently has been impressive.